The American Journal of Pathology
Volume 180, Issue 4 , Pages 1593-1602 , April 2012

Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular Dystrophy

  • Jachinta E. Rooney

      Affiliations

    • Department of Pharmacology, Center for Molecular Medicine, University of Nevada School of Medicine, Reno, Nevada
    • ,
  • Jolie R. Knapp

      Affiliations

    • Department of Pharmacology, Center for Molecular Medicine, University of Nevada School of Medicine, Reno, Nevada
    • ,
  • Bradley L. Hodges

      Affiliations

    • Prothelia Inc., Milford, Massachusetts
    • ,
  • Ryan D. Wuebbles

      Affiliations

    • Department of Pharmacology, Center for Molecular Medicine, University of Nevada School of Medicine, Reno, Nevada
    • ,
  • Dean J. Burkin

      Affiliations

    • Department of Pharmacology, Center for Molecular Medicine, University of Nevada School of Medicine, Reno, Nevada
    • Corresponding Author InformationAddress reprint requests to Dean J. Burkin, Ph.D., Department of Pharmacology, Center for Molecular Medicine, University of Nevada School of Medicine, Reno, NV 89557

,Accepted 6 December 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Cure CMD, Struggle Against Muscular Dystrophy, and R01AR053697 (D.J.B.) and R43AR057594 (B.L.H.).

 Disclosures: The University of Nevada, Reno, has a patent pending on the therapeutic use of laminin, laminin derivatives, and their compositions. The patent inventors are D.J.B. and J.E.R. The University of Nevada, Reno, has licensed this technology to Prothelia Inc., Milford, MA, and has a small equity share in this company. B.L.H. is the Chief Scientific Officer (CSO) of Prothelia, Inc. Laminin-111 protein was provided by Sigma.

 Supplemental material for this article can be found at http://ajp.amjpathol.org or at doi: 10.1016/j.ajpath.2011.12.019.

PII: S0002-9440(12)00022-3

doi: 10.1016/j.ajpath.2011.12.019

The American Journal of Pathology
Volume 180, Issue 4 , Pages 1593-1602 , April 2012

Article Tools

* Image Usage & Resolution